A mathematical model predicting anti-hepatitis B virus surface antigen (HBs) decay after vaccination against hepatitis B

被引:32
作者
Honorati, MC
Palareti, A
Dolzani, P
Busachi, CA
Rizzoli, R
Facchini, A
机构
[1] Univ Bologna, Lab Immunol & Genet, Ist Ric Codivilla Putti IOR, I-40136 Bologna, Italy
[2] Univ Bologna, Dipartimento Med Interna & Gastroenterol, I-40136 Bologna, Italy
[3] Univ Bologna, Dipartimento Sci Informaz, I-40136 Bologna, Italy
[4] Univ Chieti, Ist Morfol Umana Normale, Chieti, Italy
关键词
hepatitis B vaccination; anti-HBs; recombinant vaccine; plasma-derived vaccine; antibody kinetic;
D O I
10.1046/j.1365-2249.1999.00866.x
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The determination of serum levels of antibodies against hepatitis B virus surface antigen (anti-HBs) after hepatitis B vaccination is currently the only simple test available to predict the decay of protection and to plan the administration of booster doses. A total of 3085 vaccine recipients of plasma-derived and recombinant vaccine have been followed for 10 years to determine the kinetics of anti-HBs production and to construct a mathematical model which could efficiently predict the anti-HBs level decline. The anti-HBs peak level was reached 68 days after the last dose of recombinant vaccine and 138 days after the last dose of plasma-derived vaccines. The age of vaccinees negatively influenced the anti-HBs levels and also the time necessary to reach the anti-HBs peak. A bilogarithmic mathematical model (log(10) level, log(10) time) of anti-HBs decay has been constructed on a sample of recombinant vaccine recipients and subsequently validated on different samples of recombinant or plasma-derived vaccine recipients. Age, gender, type of vaccine (recombinant or plasma-derived), number of vaccine doses (three or four) did not influence the mathematical model of antibody decay. The program can be downloaded at the site: http://www2.stat.unibo.it/palareti/vaccine.htm. Introducing an anti-HBs determination obtained after the peak, the program calculates a prediction of individual anti-HBs decline and allows planning of an efficient booster policy.
引用
收藏
页码:121 / 126
页数:6
相关论文
共 29 条
[21]   Hepatitis B vaccine immunoresponsiveness in adolescents: A revaccination proposal after primary vaccination [J].
Minana, JS ;
Ganuza, MG ;
Millan, PF ;
Fernandez, MP .
VACCINE, 1996, 14 (02) :103-106
[22]  
NOMMENSEN FE, 1989, LANCET, V2, P847
[23]  
SAS Institute - Statistical Analysis System, 1990, SAS STAT US GUID VER, V2, P891
[24]   HEPATITIS-B VACCINE BOOSTING AMONG YOUNG HEALTHY-ADULTS [J].
TILZEY, AJ ;
PALMER, SJ ;
BANATVALA, JE ;
VINES, SK ;
GILKS, WR .
LANCET, 1994, 344 (8934) :1438-1439
[25]   HEPATITIS-B VACCINE BOOSTING - THE DEBATE CONTINUES [J].
TILZEY, AJ .
LANCET, 1995, 345 (8956) :1000-1001
[26]   Protection provided by hepatitis B vaccine in a Yupik Eskimo population - Results of a 10-year study [J].
Wainwright, RB ;
Bulkow, LR ;
Parkinson, AJ ;
Zanis, C ;
McMahon, BJ .
JOURNAL OF INFECTIOUS DISEASES, 1997, 175 (03) :674-677
[27]  
WATANAKUNAKORN C, 1994, SERODIAGN IMMUNOTHER, V6, P125
[28]   Vaccine induced immunologic memory for hepatitis B surface antigen: Implications for policy on booster vaccination [J].
West, DJ ;
Calandra, GB .
VACCINE, 1996, 14 (11) :1019-1027
[29]   IS BOOSTER INJECTION WITH HEPATITIS-B VACCINE NECESSARY IN HEALTHY RESPONDERS - A STUDY OF THE IMMUNE-RESPONSE [J].
WISMANS, PJ ;
VANHATTUM, J ;
MUDDE, GC ;
ENDEMAN, HJ ;
POEL, J ;
DEGAST, GC .
JOURNAL OF HEPATOLOGY, 1989, 8 (02) :236-240